Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1371 | Pituitary Clinical | ICEECE2012

Japan National Survey of metastatic pituitary tumor: preliminary report on 164 cases

Habu M. , YUnoue S. , Fujio S. , Shimatsu A. , Teramoto A. , Arita K.

Background and objective: The number of reports of metastatic (secondary) pituitary tumors has been increasing with progression of diagnostic and treatment skills for cancer patients. However, there were no nation-wide epidemiologic surveys or epidemiologic reviews about this topic. We have started a multi-institutional joint research in Japan to understand clinical features of metastatic pituitary tumors.Subjects and methods: We distributed 1069 closely...

ea0029p1478 | Pituitary Clinical | ICEECE2012

The results of surgical treatment on prolactinomas in females of child bearing ages

Fujio S , Habu M , Yunoue S , Hirano H , Arita K

Introduction: Medical therapy with dopaminergic drugs is the preferred initial treatment for symptomatic prolactinoma. However, some drawbacks of medical therapy are still of concern. Surgery is indicated in cases of resistance or intolerance to drugs or where patients prefer definitive cure to lifelong drug treatment. In addition, young women with small and enclosed type tumor may be good candidates for surgical treatment because of high curability and safety. We evaluated th...

ea0029p1417 | Pituitary Clinical | ICEECE2012

Limited effects of temozolomide monotherapy on aggressive pituitary tumors. -Based on our own experiences of three cases-

Habu M , Yunoue S , Fujio S , Tominaga A , Kinoshita Y , Arita K

Back ground: Encouraging responses of pituitary adenomas and pituitary carcinomas to temozolomide treatment have been well described and loss of immunopositivity of O6-methyl-guanine-DNA methyltransferase (MGMT) reportedly serves a predictor of good response. Recently some nonresponsive cases, however, also appeared. We describe here our own experiences of temozolomide treatment on three aggressive pituitary tumors.Subjects and methods: Three pitu...

ea0029p1431 | Pituitary Clinical | ICEECE2012

Relationship between gsp mutations and clinico-pathological features in GH producing pituitary adenomas

Arita K. , Bakhtiar Y. , Yunoue S. , Habu M. , Tominaga A. , Hirano H. , Yasufuku-Takano J. , Takano K.

Purpose: To know the relationship between gsp mutations and clinico-pathological features in GH producing pituitary adenomas.Subjects and methods: Somatotropinomas resected from 43 acromegalic patients, 18 males and 25 females, were examined for gsp mutation analysis. The mutation was detected in 25 of 43 (58.1%) tumours with alternations of Arg to Cys in codon 201 (68%), Arg to Ser in codon 201 (8%), Gln to Leu in codon 227 (20%) and Gln to Arg in codon...

ea0029p1498 | Pituitary Clinical | ICEECE2012

Changes in body composition in patients with acromegaly

Fujio S , Habu M , Yunoue S , Hirano H , Arimura H , Arita K

Introduction: With the advancement of surgical techniques and equipments, many patients with acromegaly have achieved complete remission after surgery. Normalization of growth hormone (GH) brings about improvement of vital prognosis, but recovery from high GH hematologic disease induces various abnormalities. We focused on the body weight and body composition of the patients with acromegaly and examined the post-surgical changes.Materials and Methods: 19...